Patents by Inventor Hendrik Schuurman

Hendrik Schuurman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations of immunosupressive agents for the treatment or prevention of graft rejections
    Publication number: 20070060511
    Abstract: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.
    Type: Application
    Filed: November 15, 2006
    Publication date: March 15, 2007
    Inventors: Hendrik Schuurman, Emanuele Cozzi, Francoise Richard, Guy Taccard, David White, Peter Friend, John Wallwork, Paolo Brenner
  • Combinations of immunosupressive agents for the treatment or prevention of graft rejections
    Publication number: 20050277585
    Abstract: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.
    Type: Application
    Filed: July 11, 2005
    Publication date: December 15, 2005
    Inventors: Hendrik Schuurman, Emanuele Cozzi, Francoise Richard, Guy Taccard, David White, Peter Friend, John Wallwork, Paolo Brenner
  • Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
    Patent number: 6455518
    Abstract: A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: September 24, 2002
    Assignee: Novartis AG
    Inventors: Gerhard Zenke, Hendrik Schuurman, Barbara Haeberlin, Armin Meinzer
  • Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
    Publication number: 20010008888
    Abstract: A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
    Type: Application
    Filed: January 11, 2001
    Publication date: July 19, 2001
    Inventors: Gerhard Zenke, Hendrik Schuurman, Barbara Haeberlin, Armin Meinzer
  • Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
    Patent number: 6239124
    Abstract: A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
    Type: Grant
    Filed: January 28, 1999
    Date of Patent: May 29, 2001
    Assignee: Novartis AG
    Inventors: Gerhard Zenke, Hendrik Schuurman, Barbara Haeberlin, Armin Meinzer